Education
About Us
Working with TipRanks
Follow Us
Exagen Inc (XGN)
NASDAQ:XGN
XGN Stock Chart & Stats
$6.43
$0.07(2.14%)
At close: 4:00 PM EST
$6.43
$0.07(2.14%)
Day’s Range― - ―
52-Week Range$2.67 - $12.23
Previous CloseN/A
Volume15.94K
Average Volume (3M)315.19K
Market Cap
$145.72M
Enterprise Value$244.63M
Total Cash (Recent Filing)$35.65M
Total Debt (Recent Filing)$28.17M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Mar 23, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding22,663,100
10 Day Avg. Volume224,483
30 Day Avg. Volume315,187
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)7.82
Price to Sales (P/S)1.34
P/FCF Ratio-5.41
Enterprise Value/Market Cap1.68
Enterprise Value/Revenue3.85
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda-17.92
Forecast
1Y Price Target
$16.20Price Target Upside151.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.87
Revenue Forecast (FY)$67.29M
Bulls Say, Bears Say
Bulls Say
Growth PotentialExagen estimates a solid long-term growth trajectory, with a current market penetration of less than 5% in a $3 billion autoimmune evaluation market.
Innovation StrategyExagen aims to launch an innovative product every 12-18 months to target unmet needs in rheumatology, with new leadership enhancing innovation.
Market ExpansionExagen's strong performance is attributed to expansion in existing accounts and execution among new customers, even amidst a client contract termination.
Bears Say
ASP ChallengesThe average selling price (ASP) was lower than expected due to a large direct bill client converting to commercial insurance, impacting ASP negatively.
Client Loss ImpactLoss of a contract with a high-billing client has created temporary headwinds for the company.
Short-Term PerformanceThe trajectory of ASP gains is slower than anticipated, impacting short-term stock performance.
Exagen News
XGN FAQ
What was Exagen Inc’s price range in the past 12 months?
Exagen Inc lowest stock price was $2.67 and its highest was $12.23 in the past 12 months.
What is Exagen Inc’s market cap?
Exagen Inc’s market cap is $145.72M.
When is Exagen Inc’s upcoming earnings report date?
Exagen Inc’s upcoming earnings report date is Mar 23, 2026 which is in 91 days.
How were Exagen Inc’s earnings last quarter?
Exagen Inc released its earnings results on Nov 04, 2025. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.157 by -$0.153.
Is Exagen Inc overvalued?
According to Wall Street analysts Exagen Inc’s price is currently Undervalued.
Does Exagen Inc pay dividends?
Exagen Inc does not currently pay dividends.
What is Exagen Inc’s EPS estimate?
Exagen Inc’s EPS estimate is -0.19.
How many shares outstanding does Exagen Inc have?
Exagen Inc has 22,663,100 shares outstanding.
What happened to Exagen Inc’s price movement after its last earnings report?
Exagen Inc reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.157. Following the earnings report the stock price went down -8.96%.
Which hedge fund is a major shareholder of Exagen Inc?
Currently, no hedge funds are holding shares in XGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exagen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.20 (151.94% Upside)
$16.20 (151.94% Upside)
Blogger Sentiment
Bullish
XGN Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 452.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $375.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
36.51%
12-Months-Change
Fundamentals
Return on Equity
-122.81%
Trailing 12-Months
Asset Growth
44.07%
Trailing 12-Months
Company Description
Exagen Inc
Exagen Inc. is a biotechnology company specializing in the development and commercialization of diagnostic tests for autoimmune diseases, particularly focusing on conditions such as lupus. The company operates in the healthcare sector and offers a range of innovative laboratory-developed tests aimed at improving the diagnosis and management of autoimmune disorders, thereby enhancing patient outcomes. Exagen's core products include the AVISE® testing platform, which provides clinicians with valuable insights into the presence and activity of autoimmune diseases based on a comprehensive analysis of patient samples.
XGN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue and volume growth, the successful launch of new products, and increased pharma services revenue. However, challenges such as the loss of a high ASP account, slower ASP gains, and increased expenses indicate areas of concern. While the company shows positive operational momentum, financial challenges balance the sentiment.View all XGN earnings summariesXGN Stock 12 Month Forecast
Average Price Target
$16.20
▲(151.94% Upside)
Technical Analysis
Ownership Overview
12.28% Insiders
5.74% Mutual Funds
20.01% Other Institutional Investors
55.81% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---